Nail onychomycosis is a fungal infection is caused by a trichophyton rubrum, trichophyton mentagrophytes, and in some cases it is caused by yeasts and molds. The major factors responsible for nail onchomycosis infection is increased exposure to worm and moist environment which leads to perfect condition for fungus to grow and proliferate. The major symptoms of onychomycosis comprises of white and yellow spots under the nail leading to discoloration, nail thickening, and formation of crumbling edges on the nail.
- This report provides in-depth analysis of the global dermatophytic onychomycosis treatment market and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatophytic onychomycosis treatment market
-
-
-
- Hospitals
- Clinics
- Independent Pharmacies
- Mail Order Pharmacies
- Drug Stores
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
-
- Valeant Pharmaceuticals International Inc.
- Galderma S.A.
- Novartis AG
- Pfizer Inc.
- Moberg Pharma AB
- Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
- Anacor Pharmaceuticals, Inc.
- NovaQuest Capital Management, L.L.C.
- Novan, Inc.
